中慧生物每股招股价12.9-15.5港元，发售3344.26万股，香港公开发售占10%，其余为国际配售，集资最 多5.18亿港元。一手200股，入场费3131.26港元。股份预期下周一(11日)上市。 格隆汇8月6日｜疫苗公司中慧生物-B(2627.HK)已于今日中午截飞，消息透露，中慧生物的公开发售部 分录得4000倍超额认购，涉资逾2100亿港元，超越今年5月上市的沪上阿姨(2589.HK)(超购约3616倍)， 成为今年超购王第三位。 据悉，有19.5万人认购中慧生物。 (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com ...

本文源自：金融界 疫苗公司中慧生物-B(2627.HK)已于今日中午截飞，消息透露，中慧生物的公开发售部分录得4000倍超 额认购，涉资逾2100亿港元，超越今年5月上市的沪上阿姨(2589.HK)(超购约3616倍)，成为今年超购王 第三位。 据悉，有19.5万人认购中慧生物。中慧生物每股招股价12.9-15.5港元，发售3344.26万股，香港公开发售 占10%，其余为国际配售，集资最多5.18亿港元。一手200股，入场费3131.26港元。股份预期下周一(11 日)上市。 ...

中慧生物，该股是港交所IPO改革前，最后一只回拨机制可达50%。目前券商孖展集资额已录得5184万元（港元，下同），超购近3360倍，已达100倍门 槛，可回拨上限50%股份予散户。 中国疫苗公司中慧生物（02627.HK）招股反应热烈，录超购近3360倍，该股原定今早截止认购，但因恶劣天气影响，招股流程将顺延一天，预计下周一 （11日）上市。在新招股流程下，香港多家券商额外开放认购时间至明天早上，包括耀才、辉立、信诚、老虎等，而富途证券则未有延长。 耀才辉立老虎信诚将加开一天 富途佣金券退还多收利息 不过，富途讯息显示，中慧生物已按既定时间今早9时截上申请，"目前我们无法受理新增或修改申请"。有关安排引起用户不满，不少人忧虑被多收一日 利息，不过富途客服在平台留言指，使用融资额度来认购新股，的确有机会较原定招股计划多收一天利息，但之后会以佣金券形式退返多收的费用。 料周五暗盘 下周一挂牌 中慧生物指，由于香港黑色暴雨警告及恶劣天气导致的极端情况，已将全球发售预期时间表推迟。根据新时间表，网上白表截止认购时间改为明天上午11 时30分；公布招购结果改为周五（8日）晚上11时，同时亦料券商展开暗盘交易；并于下周 ...

【财华社讯】中慧生物-B(02627.HK)公布，由于黑色暴雨警告及2025年8月5日上午恶劣天气导致的极端 情况，招股章程及正式通告所载的全球发售预期时间表将据此推迟。公司宣布，全球发售将采用经更新 预期时间表，预期H股将于2025年8月11日开始在联交所买卖。 本文源自：财华网 ...

Core Viewpoint - Zhonghui Biotech-B (02627.HK) has announced a delay in its global offering schedule due to extreme weather conditions, with shares now expected to begin trading on August 11, 2025, instead of the previously planned August 8, 2025 [2]. Group 1: IPO Details - The company plans to issue 33.4426 million H-shares, representing 8.5% of the total shares post-issue, with an additional 15% over-allotment option [2][3]. - The expected share price range is between HKD 12.90 and HKD 15.50, aiming to raise approximately HKD 5.18 billion [2][3]. - The IPO will involve 90% international offering and 10% public offering, with no over-allotment option [2]. Group 2: Key Investors and Underwriters - The IPO has secured one cornerstone investor, Jiaxing Xinyang, which has committed to purchasing USD 13 million (approximately HKD 102 million) of the offering [2][3]. - The joint sponsors and global coordinators for the IPO are CITIC Securities and CMB International, with other underwriters including Livermore Securities, Futu Securities, and Bank of China International [2][3]. Group 3: Company Overview - Zhonghui Biotech, established in 2015, focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new methodologies [3]. - The company aims to replace traditional and imported vaccines in China with high-end vaccines and expand its competitive advantage internationally [3]. - Zhonghui Biotech currently has one commercialized product in China and two core products in development: a quadrivalent influenza virus subunit vaccine and a lyophilized human rabies vaccine [3].

（文章来源：证券时报网） 中慧生物-B公布，由于黑色暴雨警告及2025年8月5日上午恶劣天气导致的极端情况，招股章程及正式通 告所载的全球发售预期时间表将据此推迟。公司谨此宣布，全球发售将采用经更新预期时间表，预期股 份将于2025年8月11日开始在联交所买卖。 ...

(责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 格隆汇8月5日｜中慧生物-B(2627.HK)在港交所发布公告称，由于黑色暴雨警告及2025年8月5日上午恶 劣天气导致的极端情况，招股章程及正式通告所载的全球发售预期时间表将据此推迟。全球发售将采用 经更新预期时间表，预期股份将于2025年8月11日(原定于8月8日)开始在联交所买卖。 ...

格隆汇8月5日丨中慧生物-B(02627.HK)公布，由于黑色暴雨警告及2025年8月5日上午恶劣天气导致的极 端情况，招股章程及正式通告所载的全球发售预期时间表将据此推迟。公司谨此宣布，全球发售将采用 经更新预期时间表，预期股份将于2025年8月11日开始在联交所买卖。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表聲明，並明確表示概不 會就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公告僅作說明用途，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。 潛在投資者於決定是否投資所提呈發售的 H 股前，應閱覽江蘇中慧元通生物科技股份有限公司 （「本公司」）所刊發日期為 2025 年 7 月 31 日的招股章程（「招股章程」），以獲得下文所述有關全球 發售的詳細資料。有關發售股份的投資決定應以招股章程所載資料為唯一依據。 除本公告另有界定者外，本公告所用詞彙與招股章程所界定者具有相同涵義。 Ab&B Bio-Tech CO., LTD. JS 江 蘇 中 慧 元 通 生 物 科 技 股 份 有 限 公 司 （於中華人民共和國成立的股份有限公司） 由於天氣惡劣 延遲全球發售的預期時間表 茲提述本公司日期為2025年7月31日的招股章程及正式通知（ 「 通知」）。 除另有註明外，本公告所用詞彙與招股章程及正式通知所界定者俱有相同涵 ...

Group 1: IPO Market Overview - In the past week (July 28 - August 3, 2025), seven companies submitted IPO applications in the Hong Kong market, including YunTianLiFei (688343.SH), XinWangDa (300207.SZ), and DanNuo Pharmaceutical [3][4] - Two companies passed the Hong Kong Stock Exchange hearing: TianYue Advanced (688234.SH) and YinNuo Pharmaceutical [3][4] - One new company, ZhongHui Biological (02627.HK), initiated its IPO process, with no companies successfully listed during this period [3][4] Group 2: ZhongHui Biological - ZhongHui Biological officially launched its IPO on July 31, 2025, with a global offering of 33.4426 million shares, priced between HKD 12.90 and HKD 15.50 per share [3][17] - The expected listing date on the Hong Kong Stock Exchange is August 8, 2025 [3][17] - The company has secured cornerstone investors who agreed to subscribe for shares totaling approximately HKD 102 million [17][19] Group 3: YunTianLiFei - YunTianLiFei is a leading AI company in China, focusing on the research, design, and commercialization of AI inference chips [6] - The company ranks among the top three providers of AI inference chip-related products and services in China, based on revenue statistics for 2024 [7] - For the three months ending March 31, 2025, YunTianLiFei reported revenue of RMB 264 million, a year-on-year increase of 168.2%, but incurred a net loss of RMB 85.801 million, a decrease of 37.9% year-on-year [8] Group 4: XinWangDa - XinWangDa, a global leader in lithium battery technology, aims to provide integrated solutions for green and efficient energy [8] - The company has a diverse product matrix, including energy storage systems, consumer batteries, and power batteries [8] - For the three months ending March 31, 2025, XinWangDa recorded revenue of RMB 12.289 billion, a year-on-year increase of 12.0%, and a 21.3% increase in profit attributable to shareholders [9] Group 5: DanNuo Pharmaceutical - DanNuo Pharmaceutical is a biotechnology company focused on discovering, developing, and commercializing innovative drug products for bacterial infections and related diseases [10][11] - The company has established a pipeline of seven innovative assets, with no products currently approved for commercial sale [12][14] - For the three months ending March 31, 2025, DanNuo reported a net loss of RMB 38.011 million, an increase of 36.4% year-on-year [14] Group 6: TianYue Advanced - TianYue Advanced is a leading manufacturer of wide bandgap semiconductor materials, focusing on the research and industrialization of silicon carbide substrates [15] - The company ranks among the top three global manufacturers of silicon carbide substrates based on sales revenue for 2024 [15] - For the three months ending March 31, 2025, TianYue reported revenue of RMB 408 million, a year-on-year decrease of 4.2%, and a net profit of RMB 8.518 million, a decrease of 81.5% year-on-year [16] Group 7: YinNuo Pharmaceutical - YinNuo Pharmaceutical is a science-driven biopharmaceutical company focused on providing innovative and affordable high-quality drugs for metabolic diseases [16] - The company has developed a pipeline of candidate drugs targeting diabetes and other metabolic diseases, including a core product for treating obesity and related conditions [16] - For the five months ending May 31, 2025, YinNuo reported revenue of RMB 38.144 million, with a net loss of RMB 97.875 million, an increase of 58.1% year-on-year [16]